Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4MW3O
|
|||
| Drug Name |
MK-8776
|
|||
| Synonyms |
MK-8776 Racemate; MK-8776 S-isomer; SCH900776 (Racemate); CHEMBL1643208; 6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(piperidin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine; 6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-7-amine; 891495-88-8; SCH900776 S-isomer; GTPL7943; SCHEMBL10380123; CHEBI:131165; HMS3656J19; 6-BROMO-3-(1-METHYLPYRAZOL-4-YL)-5-[(3R)-PIPERIDIN-3-YL]PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE; BCP02883; BDBM50334854; NSC764659; AKOS026750519; MK 8776; NSC-764659; NCGC00387868-02; DA-40779; BCP0726000317; FT-0700501; FT-0771683; J3.517.083I; Q27086899; SCH 900776 (CAS:891494-64-7); 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3S)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine; 6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[5,1-b]pyrimidin-7-amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hodgkin lymphoma [ICD-11: 2B30; ICD-10: C81, C81.9; ICD-9: 201] | Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H18BrN7
|
|||
| Canonical SMILES |
CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)C4CCCNC4
|
|||
| InChI |
1S/C15H18BrN7/c1-22-8-10(6-19-22)11-7-20-23-14(17)12(16)13(21-15(11)23)9-3-2-4-18-5-9/h6-9,18H,2-5,17H2,1H3
|
|||
| InChIKey |
GMIZZEXBPRLVIV-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:131165
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00779584) A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248). U.S. National Institutes of Health. | |||
| REF 2 | Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.